Concepedia

Przemysław Langiewicz

PL

4

Publications

384

Citations

4

H-Index

2009

Active since

Affiliations

P.A. Hertzen Moscow Oncology Research Institute(Current)

Georgetown Lombardi Comprehensive Cancer Center

Wojskowy Instytut Medyczny

Merck & Co., Inc., Rahway, NJ, USA (United States)

Przemysław Langiewicz is an author at P.A. Hertzen Moscow Oncology Research Institute specializing in oncology, urology, and radiation oncology.

Top concepts

Publications per year

2009–2021

4

Publications

4

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

David F. McDermott, Jae‐Lyun Lee, Marek Ziobro et al. · Journal of Clinical Oncology · 2021 · 277 citations · Full text

Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines

Sebastian Szmit, Przemysław Langiewicz, Jakub Żłnierek et al. · Kidney & Blood Pressure Research · 2011 · 44 citations · Full text

Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

Jakub Żołnierek, Paweł Nurzyński, Przemysław Langiewicz et al. · Journal of Cancer Research and Clinical Oncology · 2009 · 32 citations · Full text

, , +7

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Brian I. Rini, Michael B. Atkins, Elizabeth R. Plimack et al. · European Urology Oncology · 2021 · 31 citations

, , +7

Rows per page

1–4 of 4